Cargando…

Medical costs and utilization in patients with depression treated with adjunctive atypical antipsychotic therapy

OBJECTIVE: To compare total medical costs and utilization over a 12-month period in commercially insured patients receiving FDA-approved adjunctive atypical antipsychotics (aripiprazole, olanzapine, or quetiapine) for depression. METHODS: A retrospective claims analysis was conducted from 2005–2010...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nadkarni, Anagha, Kalsekar, Iftekhar, You, Min, Forbes, Robert, Hebden, Tony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553650/ https://www.ncbi.nlm.nih.gov/pubmed/23378778 http://dx.doi.org/10.2147/CEOR.S36526

Ejemplares similares

Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey
por: Kalsekar, Iftekhar, et al.
Publicado: (2012)

Impact of Atypical Antipsychotics as Adjunctive Therapy on Psychiatric Cost and Utilization in Patients with Major Depressive Disorder
por: Yan, Tingjian, et al.
Publicado: (2020)

Costs and Resource Utilization Among Medicaid Patients with Schizophrenia Treated with Paliperidone Palmitate or Oral Atypical Antipsychotics
por: Pesa, Jacqueline A., et al.
Publicado: (2015)

Adjunctive Atypical Antipsychotic Treatment for Major Depressive Disorder: A Meta-Analysis of Depression, Quality of Life, and Safety Outcomes
por: Spielmans, Glen I., et al.
Publicado: (2013)

Utilization and Costs for Compliant Patients Initiating Therapy With Pioglitazone or Rosiglitazone Versus Insulin in a Medicaid Fee-for-Service Population
por: Kalsekar, Iftekhar, et al.
Publicado: (2006)

Comparative Treatment Patterns, Resource Utilization, and Costs in Stimulant-Treated Children with ADHD Who Require Subsequent Pharmacotherapy with Atypical Antipsychotics Versus Non-Antipsychotics
por: Sikirica, Vanja, et al.
Publicado: (2012)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
por: Jeon, Sang Won, et al.
Publicado: (2017)

New Atypical Antipsychotics in the Treatment of Schizophrenia and Depression
por: Orzelska-Górka, Jolanta, et al.
Publicado: (2022)

Cardiotoxicity of current antipsychotics: Newer antipsychotics or adjunct therapy?
por: Liu, Zheng, et al.
Publicado: (2022)

Atypical antipsychotics to treat the neuropsychiatric symptoms of dementia
por: Lee, Philip E, et al.
Publicado: (2006)

Atypical antipsychotics as add-on treatment in late-life depression
por: Cakir, Sibel, et al.
Publicado: (2016)

Health care resource utilization and direct medical costs for patients with schizophrenia initiating treatment with atypical versus typical antipsychotics in Tianjin, China
por: He, Xiaoning, et al.
Publicado: (2015)

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
por: Frois, Christian, et al.
Publicado: (2013)

One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis
por: Kim, Edward, et al.
Publicado: (2011)

Asenapine: an atypical antipsychotic with atypical formulations
por: Musselman, Meghan, et al.
Publicado: (2021)

Atypical antipsychotics, more than just an antipsychotic
por: Tendilla-Beltrán, Hiram, et al.
Publicado: (2020)

Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial
por: Gupta, Bhanu, et al.
Publicado: (2021)

Efficacy and safety of treating patients with refractory schizophrenia with antipsychotic medication and adjunctive electroconvulsive therapy: a systematic review and meta-analysis
por: WANG, Wenzheng, et al.
Publicado: (2015)

Severity in schizophrenia patients receiving atypical antipsychotic medications
por: Alam Fatmi1j, Syed Meraj, et al.
Publicado: (2022)

Health-related quality of life in patients treated with atypical antipsychotics
por: de Almeida, Juliana L., et al.
Publicado: (2020)

The Use of Atypical Antipsychotics in Treating a Pediatric Psychiatric Patient
por: Jogie, Joshua A, et al.
Publicado: (2022)

Call to Caution with the Use of Atypical Antipsychotics for Treatment of Depression in Older Adults
por: Amodeo, Katherine, et al.
Publicado: (2016)

Atypical antipsychotics, dystonia, and psychotic depression: old solutions for new problems
por: Gazzellone, Matthew J., et al.
Publicado: (2022)

Efficacy and safety of haloperidol versus atypical antipsychotic medications in the treatment of delirium
por: Yoon, Hyung-Jun, et al.
Publicado: (2013)

Hospitalization Risk for Adults with Bipolar I Disorder Treated with Oral Atypical Antipsychotics as Adjunctive Therapy with Mood Stabilizers: A Retrospective Analysis of Medicaid Claims Data
por: Niu, Xiaoli, et al.
Publicado: (2021)

Stimulant and Atypical Antipsychotic Medications For Children Placed in Foster Homes
por: Linares, L. Oriana, et al.
Publicado: (2013)

Gender differences in the use of atypical antipsychotic medications for ICU delirium
por: Karamchandani, Kunal, et al.
Publicado: (2018)

Associated mortality risk of atypical antipsychotic medication in individuals with dementia
por: Phiri, Peter, et al.
Publicado: (2022)

Use of Conventional Antipsychotics and the Cost of Treating Schizophrenia
por: Lyu, Ramon R., et al.
Publicado: (2001)

Cost-effectiveness of early responders versus early nonresponders to atypical antipsychotic therapy
por: Peng, Xiaomei, et al.
Publicado: (2011)

Long-term cost-effectiveness of atypical antipsychotics in the treatment of adults with schizophrenia in the US
por: O’Day, Ken, et al.
Publicado: (2013)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
por: Faries, Douglas, et al.
Publicado: (2005)

Atypical Antipsychotics and Other Therapeutic Options for Treatment of Resistant Major Depressive Disorder
por: Seo, Rubo J., et al.
Publicado: (2010)

Serum prolactin levels and sexual dysfunction in patients with schizophrenia treated with antipsychotics: comparison between aripiprazole and other atypical antipsychotics
por: Kirino, Eiji
Publicado: (2017)

Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand
por: Boonlue, Tuanthon, et al.
Publicado: (2016)

Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil
por: Barbosa, Wallace Breno, et al.
Publicado: (2018)

Attentional and emotional functioning in schizophrenia patients treated with conventional and atypical antipsychotic drugs
por: Kucharska-Pietura, Katarzyna, et al.
Publicado: (2012)

Genotype-phenotype Analysis of Paraoxonase 1 in Schizophrenic Patients Treated with Atypical Antipsychotics
por: Pavăl, Denis, et al.
Publicado: (2018)

Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics
por: Chen, Yi-Lung, et al.
Publicado: (2018)

Atypical antipsychotics and delirium in critical care
por: Wise, Matt P, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_al81f91m516l35rp73i8l3g6gd